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Original Article

Myeloablative Autologous Stem-Cell
Transplantation for Severe Scleroderma
K.M. Sullivan, E.A. Goldmuntz, L. Keyes‑Elstein, P.A. McSweeney, A. Pinckney,
B. Welch, M.D. Mayes, R.A. Nash, L.J. Crofford, B. Eggleston, S. Castina,
L.M. Griffith, J.S. Goldstein, D. Wallace, O. Craciunescu, D. Khanna, R.J. Folz,
J. Goldin, E.W. St. Clair, J.R. Seibold, K. Phillips, S. Mineishi, R.W. Simms,
K. Ballen, M.H. Wener, G.E. Georges, S. Heimfeld, C. Hosing, S. Forman,
S. Kafaja, R.M. Silver, L. Griffing, J. Storek, S. LeClercq, R. Brasington, M.E. Csuka,
C. Bredeson, C. Keever‑Taylor, R.T. Domsic, M.B. Kahaleh, T. Medsger,
and D.E. Furst, for the SCOT Study Investigators*

A BS T R AC T
BACKGROUND

Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has
a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 monthly infusions of cyclophosphamide in patients with scleroderma.
METHODS

We randomly assigned adults (18 to 69 years of age) with severe scleroderma to undergo
myeloablative autologous stem-cell transplantation (36 participants) or to receive cyclophosphamide (39 participants). The primary end point was a global rank composite
score comparing participants with each other on the basis of a hierarchy of disease
features assessed at 54 months: death, event-free survival (survival without respiratory,
renal, or cardiac failure), forced vital capacity, the score on the Disability Index of the
Health Assessment Questionnaire, and the modified Rodnan skin score.
RESULTS

In the intention-to-treat population, global rank composite scores at 54 months showed
the superiority of transplantation (67% of 1404 pairwise comparisons favored transplantation and 33% favored cyclophosphamide, P = 0.01). In the per-protocol population
(participants who received a transplant or completed ≥9 doses of cyclophosphamide), the
rate of event-free survival at 54 months was 79% in the transplantation group and 50%
in the cyclophosphamide group (P = 0.02). At 72 months, Kaplan–Meier estimates of
event-free survival (74% vs. 47%) and overall survival (86% vs. 51%) also favored transplantation (P = 0.03 and 0.02, respectively). A total of 9% of the participants in the transplantation group had initiated disease-modifying antirheumatic drugs (DMARDs) by 54
months, as compared with 44% of those in the cyclophosphamide group (P = 0.001).
Treatment-related mortality in the transplantation group was 3% at 54 months and 6%
at 72 months, as compared with 0% in the cyclophosphamide group.

The authors’ full names, academic degrees, and affiliations are listed in the
Appendix. Address reprint requests to Dr.
Sullivan at the Cellular Therapy Program,
Department of Medicine, Box 3961, Duke
University Medical Center, Durham, NC
27710, or at keith.sullivan@duke.edu.
* A complete list of the SCOT study sites,
collaborators, and personnel is provided
in the Supplementary Appendix, available at NEJM.org.
Drs. Goldmuntz and Keyes-Elstein contributed equally to this article.
N Engl J Med 2018;378:35-47.
DOI: 10.1056/NEJMoa1703327
Copyright © 2018 Massachusetts Medical Society.

CONCLUSIONS

Myeloablative autologous hematopoietic stem-cell transplantation achieved long-term
benefits in patients with scleroderma, including improved event-free and overall survival,
at a cost of increased expected toxicity. Rates of treatment-related death and post-transplantation use of DMARDs were lower than those in previous reports of nonmyeloablative transplantation. (Funded by the National Institute of Allergy and Infectious Diseases and the National Institutes of Health; ClinicalTrials.gov number, NCT00114530.)
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cleroderma with internal-organ
involvement (diffuse cutaneous systemic
sclerosis) is a devastating autoimmune disorder. Despite advances in management, mortality
driven by pulmonary involvement has not changed
in 40 years.1-3 Although disease-modifying antirheumatic drugs (DMARDs) and biologics have
been studied, none have shown lasting benefit,
and only cyclophosphamide given for 12 months
has shown short-term benefit as compared with
placebo.4-6 For many patients, scleroderma is a
fatal disease.
Pilot studies of autologous hematopoietic stemcell transplantation in scleroderma showed improvement in skin sclerosis and stabilization of
pulmonary function.7-10 Two randomized trials
of nonmyeloablative transplantation also showed
benefit11,12; however, neither trial changed clinical practice in the United States, in part owing
to concerns about durability of response and the
safety of transplantation.13 Our trial (Scleroderma:
Cyclophosphamide or Transplantation [SCOT])
tests a different therapeutic approach: myelo
ablation with total-body irradiation followed by
reconstitution with a CD34+ selected autograft
versus cyclophosphamide. We hypothesized that
myeloablative transplantation would result in better long-term outcomes than cyclophosphamide
treatment. Participants were followed closely
over a period of 4.5 years to assess safety and
durability of remission. The primary end point,
assessed at 54 months, was a global rank composite score based on a hierarchy of disease
features.

Me thods
Trial Design, Interventions, and Oversight

This randomized, open-label, phase 2 trial was
conducted at 26 sites (Table S1 in the Supplementary Appendix, available with the full text of this
article at NEJM.org). Randomization was performed on a 1:1 basis and stratified according to
site, with the difference in the number of participants in the two treatment groups constrained to
two or fewer at each site.14 The trial ended when
the last participant completed the month 54 evaluation, with a maximum follow-up to 72 months.
After an event of respiratory, renal, or cardiac
failure occurred (i.e., event-free survival was not
achieved), clinic visits ended but telephone contacts continued to month 54. Death was investigated with the use of public records, as needed.
36
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Hematopoietic progenitors were mobilized with
granulocyte colony-stimulating factor (G-CSF);
after leukapheresis and CD34+ cell enrichment,
the autologous product was cryopreserved.15 Fractionated total-body irradiation (800 cGy), cyclophosphamide (120 mg per kilogram of body
weight), and equine antithymocyte globulin
(90 mg per kilogram) were given as previously
reported.9,16 Pulmonary and renal shields limited
organ exposure to a target of 200 cGy.17 After
conditioning, participants received CD34+ cells
(median, 5.6×106 per kilogram; interquartile
range, 3.8 to 6.0) and post-transplantation care
with G-CSF, glucocorticoids, lisinopril, and antiinfective agents including acyclovir, which was
given for 1 year (Table S2 in the Supplementary
Appendix).9,18 In the cyclophosphamide group,
an initial intravenous dose of 500 mg per square
meter of body-surface area was followed by 11
monthly infusions of 750 mg per square meter
with mesna prophylaxis.
A data and safety monitoring board appointed by the National Institute of Allergy and Infectious Diseases, the trial sponsor, provided oversight. An independent end-point review committee
whose members were aware of the trial-group
assignments verified causes of death and verified
events of respiratory, renal, or cardiac failure.
Institutional review boards at each site approved
the protocol, and Rho (Chapel Hill, NC) held and
analyzed the data. Members of the steering committee (Table S1 in the Supplementary Appendix) designed the trial, vouch for its adherence
to the protocol, and attest to the accuracy and
completeness of the data and analyses as specified in the protocol and statistical analysis plan,
which are available at NEJM.org. The trial data
are accessible from ImmPort (www.immport.org)
in study SDY1039 (DOI: 10.21430/M3SM4LTLH).
The first author wrote the initial draft, and all
the coauthors reviewed the manuscript and
agreed to publication. All the participants in the
trial provided written informed consent.
Participants

Adults (18 to 69 years of age) with scleroderma
(American College of Rheumatology 1995 criteria) for 5 years or less with pulmonary or renal
involvement were eligible. Pulmonary involvement
required active interstitial lung disease (as determined by bronchoalveolar cell composition or
ground-glass opacities on computed tomography
of the chest) plus either a forced vital capacity
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(FVC) or a diffusing capacity of the lung for
carbon monoxide (DLco) of less than 70% of the
predicted value. Renal involvement required previous scleroderma-related renal disease. Key exclusion criteria were active gastric antral vascular
ectasia, a DLco of less than 40% of the predicted
value, an FVC of less than 45% of the predicted
value, a left ventricular ejection fraction of less
than 50%, a creatinine clearance of less than 40 ml
per minute, pulmonary arterial hypertension, or
more than 6 months of previous treatment with
cyclophosphamide.19,20
Evaluations and End Points

Participants were evaluated monthly through
year 1, then approximately quarterly through
year 5. Serial pulmonary-function testing was
performed in the same laboratory, with DLco
(Crapo–Morris calculation) corrected for anemia.
Rheumatologists were certified to assess the
modified Rodnan skin score (range, 0 [normal]
to 51 [severe skin thickening]); minimally important differences are 3.2 to 5.3 points. Scales
are more fully detailed in Section S1 of Methods
in the Supplementary Appendix.21,22
The primary end point was the global rank
composite score at 54 months. The global rank
composite score is an analytic tool that accounts
for multiple disease manifestations simultaneously but does not measure disease activity or
severity. It reflects how participants compare
with one another on the basis of a hierarchy of
ordered outcomes: death, event-free survival (survival without respiratory, renal, or cardiac failure), FVC, the score on the Disability Index of
the Health Assessment Questionnaire (HAQ-DI;
range, 0 to 3, with higher scores indicating more
disability), and the modified Rodnan skin score
(Section S1 of Methods in the Supplementary
Appendix). Participants who were alive at 54
months rank higher than those who died; those
who survived event-free rank higher than those
who had an event, and so forth down the hierarchy (Sections S2 and S3 of Methods in the
Supplementary Appendix). With the assumption
that transplant recipients would have worse
early outcomes but could fare better long-term
than participants in the comparison group, the
global rank composite score is intentionally constructed to treat early and late deaths (or events
of organ failure) as equal, irrespective of timing.
Variables that were used to define an event included death, respiratory failure (decrease from
n engl j med 378;1

baseline of >30% in percent predicted DLco or
>20% in percent predicted FVC) (Section S2 of
Methods in the Supplementary Appendix), renal
failure (long-term dialysis or renal transplantation), or cardiac failure (clinical congestive heart
failure or left ventricular ejection fraction <30%).
The lowest three components of the global
rank composite score are ordinal. They were
defined by improvement (increase of ≥10% in
the percentage of the predicted FVC, decrease of
>0.4 in the HAQ-DI score, or decrease of ≥25%
in the modified Rodnan skin score, as compared
with baseline values), no change (neither improvement nor worsening), or worsening (decrease
from baseline of ≥10% in the percentage of the
predicted FVC, increase of >0.4 in the HAQ-DI
score, or increase of ≥25% in the modified Rodnan skin score, as compared with baseline values).
Secondary end points included individual components of the global rank composite score,
measures of disease progression, and quality of
life. Safety end points included treatment-related
death, death from any cause, treatment-related
toxic effects, infections, and hematologic engraftment. Deaths, cancers, and disease-progression
events that occurred after an event of respiratory,
renal, or cardiac failure were tracked as secondary end points but were not reported as adverse
events.
Statistical Analysis

The trial was originally designed for 226 participants, with event-free survival as the primary
end point. Low accrual prompted amendments,
first to broaden entry criteria, then, ultimately,
to reduce the sample size by changing the primary end point to the global rank composite
score. Power for the new design with 114 participants was estimated by simulations at 93%
for a two-sided test with an alpha level of 0.05.
Assumptions for the simulations were guided by
data on similarly treated patients involved in
previous studies.4,9 No SCOT data informed the
redesign process (details in Section S3 of Methods in the Supplementary Appendix). With continued slow accrual but without reviewing efficacy results, the data and safety monitoring
board recommended stopping randomization at
75 participants.
For ordinal end points, including the global
rank composite score, the Wilcoxon signed-rank
test was used for comparisons; the van Elteren
extension of the Wilcoxon signed-rank test was
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Figure 1. Participant Milestones.
Milestones for each participant assigned to undergo
myeloablative hematopoietic stem-cell transplantation
(Panel A) or to receive cyclophosphamide (Panel B) are
depicted from the time of informed consent. Organ failure refers to respiratory, renal, or cardiac failure. For early
withdrawals from the trial, death was investigated with
the use of site and public records. In Panels A and B,
each black hash mark represents a clinical evaluation
with pulmonary-function tests at the transplantation
center. In Panel B, the asterisk identifies a participant
who gave consent more than 12 months before randomization. The vertical dashed line at 54 months indicates
participant status at the time of the primary end point.

used for stratified analyses.23,24 The effect size
for the Wilcoxon signed-rank test is reported as
the percent of all possible pairs between the two
groups that favor transplantation (or cyclophosphamide). Fisher’s exact test was used for dichotomous events, including death and event-free survival at 54 and 48 months; the Mantel–Haenszel
chi-square test was used for stratified analysis.
Kaplan–Meier survival curves were compared
with the use of log-rank tests. The data and
safety monitoring board reviewed four prespecified futility analyses that included an ability to
stop for efficacy with P<0.0001, leaving an alpha
level of 0.0496 for the primary intention-to-treat
analysis of the global rank composite score at
54 months after randomization. The intention-totreat population was defined as all the participants who had undergone randomization. Secondary analyses are presented for the per-protocol
population, defined as participants who received
a transplant or completed nine or more doses of
cyclophosphamide. Secondary analyses are supportive; P values were not adjusted for multiple
comparisons. Safety results are summarized for
all the participants who initiated treatment. Analyses used SAS software, version 9.3 or higher.

*
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From July 2005 through September 2011, a total
of 75 of the 205 screened patients underwent
randomization. Patients who did not meet entry
criteria or who were denied insurance coverage
accounted for the majority of screening failures
(Fig. S1 in the Supplementary Appendix). In the
transplantation group (36 participants), 34 initi-
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Table 1. Demographic and Clinical Characteristics at Baseline (Intention-to-Treat Population).*
Characteristic

Transplantation
(N = 36)

Cyclophosphamide
(N = 39)

Total
(N = 75)

Mean age — yr

44.9±10.9

46.9±10.4

45.9±10.6

19 (53)

29 (74)

48 (64)

White

29 (81)

31 (79)

60 (80)

Black

2 (6)

4 (10)

6 (8)

Other

5 (14)

4 (10)

9 (12)
24 (32)

Female sex — no. (%)
Race — no. (%)†

Smoking status — no. (%)
Current or former smoker

14 (39)

10 (26)

Never smoked

22 (61)

29 (74)

51 (68)

Mean duration of scleroderma before
randomization — mo

25.1±12.9

29.0±16.0

27.1±14.6

DMARD use in previous 6 mo — no. (%)

26 (72)

25 (64)

51 (68)

8 (22)

17 (44)

25 (33)

Previous use of cyclophosphamide — no. (%)
Lung involvement — no. (%)

36 (100)

37 (95)

73 (97)

Mean modified Rodnan skin score‡

28.5±8.7

30.8±10.5

29.7±9.7

Mean FVC — % of predicted value

74.5±14.8

73.8±17.0

74.1±15.9

Mean DLco — % of predicted value

53.9±7.6

52.7±8.2

53.3±7.9

Mean left ventricular ejection fraction — %§

61.0±6.1

59.9±4.3

60.4±5.2

122.8±41.7

124.9±54.3

123.9±48.3

29.8±26.5

32.2±24.9

31.1±25.4

Mean creatinine clearance — ml/min
Mean ESR — mm/hr¶
Mean SF-36 physical component score‖

29.5±9.2

28.9±9.5

29.2±9.3

Mean SF-36 mental component score‖

44.7±10.7

44.6±9.9

44.6±10.2

1.2±0.6

1.4±0.9

1.3±0.8

Mean HAQ-DI score**

*	Plus–minus values are means ±SD. Although the between-group differences for sex, smoking status, and previous use of
cyclophosphamide appear potentially clinically relevant, no P values for comparisons between the two groups were less
than 0.05, on the basis of t-tests for numerical variables and Fisher’s exact test for categorical variables. P = 0.06 for sex,
0.39 for smoking status, and 0.06 for previous use of cyclophosphamide. Additional data on participant characteristics
are provided in Table S3 in the Supplementary Appendix. DLco denotes diffusing capacity of the lung for carbon monoxide, DMARD disease-modifying antirheumatic drug, ESR erythrocyte sedimentation rate, and FVC forced vital capacity.
†	Race was reported by the participant.
‡	Modified Rodnan skin scores range from 0 (normal) to 51 (severe skin thickening).
§	Data were available for 36 participants in the transplantation group and 37 in the cyclophosphamide group.
¶	Data were available for 29 participants in the transplantation group and 34 in the cyclophosphamide group.
‖	Scores on the physical and mental components of the 36-Item Short Form General Health Survey (SF-36) range from
0 to 100, with higher scores indicating better quality of life. Data were available for 35 participants in the transplantation group and 35 in the cyclophosphamide group.
**	Scores on the Disability Index of the Health Assessment Questionnaire (HAQ-DI) range from 0 to 3, with higher
scores indicating more disability. Data were available for 35 participants in the transplantation group and 38 in the
cyclophosphamide group.

ated mobilization and 33 received a transplant.
In the cyclophosphamide group (39 participants),
37 initiated treatment; 32 received 12 doses and
34 received 9 or more doses. Of the 75 participants, 46 (27 in the transplantation group and
19 in the cyclophosphamide group) completed
the trial, 14 (3 in the transplantation group and
11 in the cyclophosphamide group) died during

n engl j med 378;1

the trial, and 15 (6 in the transplantation group
and 9 in the cyclophosphamide group) withdrew
prematurely (Fig. 1, and Fig. S1 in the Supplementary Appendix).
Baseline characteristics reflected severe scleroderma: the mean modified Rodnan skin score
was 30, the mean DLco was 53% of the predicted value, and 97% of the participants had
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pulmonary involvement (Table 1, and Table S3 in
the Supplementary Appendix). The two groups had
similar characteristics except that the cyclophosphamide group had more female participants,
participants who had never smoked, and participants who had previously used cyclophosphamide
than the transplantation group. Reasons for the
imbalance are unknown.
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Efficacy

In the intention-to-treat population, the global
rank composite score favored transplantation at
54 months (prespecified primary end point) and
48 months (key secondary end point); the percent
of 1404 (36 × 39) pairwise comparisons favoring
transplantation over cyclophosphamide was 67%
versus 33% at 54 months (P = 0.01) and 68% ver-

Table 2. Efficacy End Points (Intention-to-Treat and Per-Protocol Populations).*
Variable

Transplantation

Cyclophosphamide

P Value†

36

39

17.0 (−58 to 52)

−6.0 (−58 to 52)

66.6

33.4

20.0 (−58 to 55)

−8.0 (−58 to 55)

67.6

32.4

By 54 mo

10 (28)

20 (51)

0.06

By 48 mo

10 (28)

20 (51)

0.06

By 54 mo

6 (17)

11 (28)

0.28

By 48 mo

6 (17)

11 (28)

0.28

Intention-to-treat population
No. of participants
Primary efficacy end point: GRCS at 54 mo‡
Median (range)
Percent of favorable pairwise comparisons

0.01

GRCS at 48 mo‡
Median (range)
Percent of favorable pairwise comparisons

0.008

Death or respiratory, renal, or cardiac failure — no. (%)

Death from any cause — no. (%)

Treatment-related death — no. (%)§
By 54 mo

1 (3)

0

0.48

By 48 mo

1 (3)

0

0.48

33

34

16.0 (−56 to 46)

−11.0 (−56 to 46)

70.1

29.9

17 (−56 to 49)

−13.0 (−56 to 49)

71.3

28.7

By 54 mo

7 (21)

17 (50)

0.02

By 48 mo

7 (21)

17 (50)

0.02

By 54 mo

3 (9)

8 (24)

0.19

By 48 mo

3 (9)

8 (24)

0.19

By 54 mo

1 (3)

0

0.49

By 48 mo

1 (3)

0

0.49

Per-protocol population
No. of participants
GRCS at 54 mo‡
Median (range)
Percent of favorable pairwise comparisons

0.004

GRCS at 48 mo‡
Median (range)
Percent of favorable pairwise comparisons

0.003

Death or respiratory, renal, or cardiac failure — no. (%)

Death from any cause — no. (%)

Treatment-related death — no. (%)§

40
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Table 2. (Continued.)
Variable

Transplantation

Cyclophosphamide

P Value†

Initiated DMARDs¶

3 (9)

15 (44)

0.001

New or worsening arrhythmia

6 (18)

4 (12)

0.46

0

4 (12)

0.04

Disease-progression event by 54 mo — no. (%)

Congestive heart failure leading to treatment

2 (6)

0

0.15

Pulmonary arterial hypertension

Clinically significant pericardial effusion

0

5 (15)

0.02

Scleroderma-related renal crisis

0

1 (3)

0.32

1 (3)

0

0.31

Myositis

*	The intention-to-treat population was defined as all the participants who had undergone randomization. The per-protocol population was defined as participants who received a transplant or completed nine or more doses of cyclophosphamide. Because pulmonary and renal toxic effects are expected and reversible during the recovery period after autologous stem-cell transplantation, events of respiratory failure or renal failure were not evaluated in either treatment group
until month 14 and month 8, respectively.
†	For the global rank composite score (GRCS), P values are based on the Wilcoxon signed-rank test. For death with or
without respiratory, renal, or cardiac failure, P values are based on Fisher’s exact test. For disease-progression events
by 54 months, P values are based on Pearson’s chi-square test.
‡	The range for the GRCS is sample specific and depends on the number of participants included in the analysis and the
number of ties in score. The higher the score, the better the participant’s performance relative to others in the sample.
Percent refers to the percent of pairwise comparisons between participants that favored transplantation or cyclophosphamide. For example, in the intention-to-treat analysis at 54 months, with 36 participants in the transplantation group
and 39 in the cyclophosphamide group, there were 1404 possible pairwise comparisons (i.e., 36 × 39). In 935 of the
1404 paired comparisons (66.6%), the global rank composite score favored transplantation.
§	“Related” includes events that were deemed to be probably or definitely related to the treatment regimen or CD34+ hematopoietic progenitor cells, as reported by the site investigator. By 72 months, there were 2 deaths (6%) in the transplantation group and 0 in the cyclophosphamide group (intention-to-treat and per-protocol populations).
¶	By 24 months, a total of three participants (9%) in the transplantation group and seven participants (21%) in the cyclophosphamide group had initiated disease-modifying antirheumatic drugs (DMARDs).

sus 32% at 48 months (P = 0.008) (Table 2 and
Fig. 2). In the per-protocol population, the percent of comparisons favoring transplantation on
the global rank composite score was 70% versus
30% at 54 months (P = 0.004) and 71% versus
29% at 48 months (P = 0.003) (Table 2).
Results of prespecified secondary analyses of
event-free survival corroborate the compositescore results. In the per-protocol population, the
rate of event-free survival at 54 months was 79%
in the transplantation group and 50% in the cyclophosphamide group (P = 0.02) (Table 2). Most
events of organ failure were respiratory failure
(in 5 participants in the transplantation group
and 13 in the cyclophosphamide group); renal
failure occurred in 1 participant in the transplantation group, and cardiac failure occurred in
1 participant in the cyclophosphamide group. In
the per-protocol analysis, Kaplan–Meier estimates
for the treatment groups begin to separate in
favor of transplantation at approximately 2 years.
At 72 months, the rate of event-free survival was
74% in the transplantation group and 47% in the
n engl j med 378;1

cyclophosphamide group (P = 0.03), and the rate
of overall survival was 86% and 51%, respectively (P = 0.02) (Fig. 2). Results of the intentionto-treat analysis were consistent with these findings (Fig. 2).
In the per-protocol population at 54 months,
the percentage of participants who had initiated
DMARDs was lower in the transplantation group
than in the cyclophosphamide group (9% vs.
44%, P = 0.001) (Table 2). No participants in the
transplantation group had had congestive heart
failure or pulmonary arterial hypertension, as
compared with 12% and 15%, respectively, of
the participants in the cyclophosphamide group
(P = 0.04 and P = 0.02, respectively). Both among
participants who had survived event-free (at 54
months) and among those who had died or had
had organ failure (at last assessment), the transplantation group was more likely than the cyclophosphamide group to show improvements on
prespecified secondary clinical end points, including the modified Rodnan skin score (100%
vs. 82% among those who survived event-free
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Figure 2 (facing page). Primary and Key Secondary
Outcomes.
Panel A shows the distribution of global rank composite
scores (GRCSs) at month 54 in the intention-to-treat
population according to treatment group. Black represents deaths (score, −58). Remaining scores range
from −30 to 52 on a red (worst)–yellow–green (best)
scale. P = 0.01 for the comparison between treatment
groups (Wilcoxon signed-rank test). Panel B shows
components of the GRCS at month 54 for participants
in the intention-to-treat population. Each row represents
an individual participant. In the first column, black indicates death at month 54 and white indicates alive. In the
second column, dark gray indicates an event of respiratory, renal, or cardiac failure; light gray indicates no event
of respiratory, renal, or cardiac failure; and blank indicates
that event-free survival (EFS) status could not be evaluated at month 54. In columns 3 through 5 (percent of
predicted forced vital capacity [FVC], score on the Disability Index of the Health Assessment Questionnaire
[HAQ-DI], and modified Rodnan skin score [mRSS]),
green represents improvement, yellow no change, and
red worsening, as compared with baseline values. All
deaths (black) are treated equally. The figure shows
the last available assessment before death, but boxes
are faded to indicate that these steps in the hierarchy
were not used for GRCS evaluation. Similarly, if EFS
status could not be evaluated (blank), the outcome
status for the last available assessments is shown as
faded, and participants were ranked on the basis of
survival status alone. Panel C shows the Kaplan–Meier
estimates of overall survival and event-free survival in
the intention-to-treat population (all the participants
who had undergone randomization), and Panel D shows
such estimates in the per-protocol population (participants who received a transplant or completed ≥9 doses
of cyclophosphamide). In Panels C and D, the vertical
dashed line represents the 54-month time point.

and 71% vs. 29% among those who had died or
had had organ failure), the HAQ-DI score (65%
vs. 35% and 29% vs. 0%), and the score on the
physical component of the 36-Item Short Form
General Health Survey (SF-36) (73% vs. 35% and
14% vs. 0%) (Fig. S2 in the Supplementary Appendix).
In post hoc analyses controlling individually
for between-group imbalances at baseline with
respect to sex, smoking status, and previous use
of cyclophosphamide, outcomes favored transplantation over cyclophosphamide on the global
rank composite score at 54 months. Within individual strata, with the exception of current or
former smokers, pairwise comparisons favored

n engl j med 378;1

transplantation (range, 56 to 77% of comparisons), with the greatest benefit noted for participants who had never smoked (P≤0.04 for all
three stratified analyses) (Table S4 in the Supplementary Appendix). Findings for covariateadjusted analyses of event-free survival at 54
months were consistent with these findings
(Table S4 in the Supplementary Appendix). Post
hoc sensitivity analyses that used different assumptions to handle missing data on event-free
survival at 54 months in computing the global
rank composite score also support the primary
end-point analysis (Table S5 in the Supplementary Appendix).
Safety, Infection, and Engraftment

A total of 21 deaths occurred over a period of
72 months (Table 3 and Fig. 1). Deaths after 54
months did not contribute to the primary end
point. Of the 7 participants in the transplantation group who died, 3 did not receive the transplant; 2 died of treatment-related causes, at months
17 and 70, after a diagnosis of the myelodysplastic syndrome; and 2 had already had an event of
respiratory, renal, or cardiac failure. No transplant recipient died within a year after transplantation. The 14 participants in the cyclophosphamide group who died included 3 who received
five or fewer doses and 7 who had already had
an event of respiratory, renal, or cardiac failure.
No deaths were attributable directly to cyclophosphamide.
Over a period of 72 months, the percentage of
participants who had serious adverse events was
lower in the cyclophosphamide group than in the
transplantation group (51% and 74%, respectively).
However, after we accounted for the duration of
follow-up, the rate of serious adverse events in
person-years was 0.38 in the transplantation
group and 0.52 in the cyclophosphamide group
(P = 0.08) (Table S6 in the Supplementary Appendix). In the transplantation group, 96% of serious
adverse events occurred in the first 26 months,
as compared with 71% of serious adverse events
in the cyclophosphamide group (Fig. S3 in the
Supplementary Appendix). The percentage of participants who had an adverse event of grade 3 or
more was higher in the transplantation group
than in the cyclophosphamide group (100% vs.
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Table 3. Deaths during the 72-Month Trial Period (Intention-to-Treat Population).
Group and Time from
Randomization to Death

Site-Reported Cause of Death

Completed Treatment

Cyclophosphamide group
1.7 Mo

Pulmonary embolism

No (2 doses of cyclophosphamide)
No (5 doses of cyclophosphamide)

6.6 Mo

Respiratory failure

18.2 Mo

Scleroderma

Yes

24.5 Mo

Scleroderma*

Yes

25.4 Mo

Septic shock

Yes

27.2 Mo

Pulmonary hypertension

Yes

29.3 Mo

Respiratory*

Yes

29.3 Mo

Respiratory failure*

32.3 Mo

Unknown cause†

35.7 Mo

Respiratory failure

Yes

39.4 Mo

Arrhythmia*

Yes

54.7 Mo‡

Infection*

Yes

68.9 Mo‡

Progression of systemic sclerosis*†

Yes

69.8 Mo‡

Sepsis*†

Yes

Yes
No (0 doses of cyclophosphamide)

Transplantation group
2.4 Mo

Unknown cause

No (no mobilization, conditioning, or
transplantation)

2.6 Mo

Pulmonary alveolar hemorrhage

9.3 Mo

Unknown cause

16.9 Mo

Enterococcal meningitis§

Yes

23.9 Mo

Respiratory*

Yes

24.1 Mo

Metabolic*†

Yes

69.9 Mo‡

Acute myeloid leukemia§

Yes

No (no conditioning or transplantation)
No (no mobilization, conditioning, or
transplantation)

*	The participant had had an event of respiratory, renal, or cardiac failure before death.
†	Death was identified through site contact or public records after participant withdrawal or trial completion.
‡	Deaths after 54 months were not counted in the primary end-point analyses.
§	Death occurred after a diagnosis of the myelodysplastic syndrome.

84%); the event rate per person-year was also
higher (2.0 vs. 1.2, P<0.001). In the transplantation group, 95% of adverse events of grade 3 or
more occurred during the first 26 months, of
which 50% were expected cytopenias (Tables S6
and S7 and Fig. S3 in the Supplementary Appendix). We noted cancers in four participants: three
in the transplantation group (one had papillary
thyroid cancer and two had the myelodysplastic
syndrome) and one in the cyclophosphamide
group (who had breast cancer).
The rate of infections (of any grade) per person-year were similar in the two groups (0.75 in
the transplantation group and 0.79 in the cyclophosphamide group) (Tables S8 through S10 in
44
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the Supplementary Appendix). However, the rate
of infections of grade 3 or more per person-year
was higher in the transplantation group than
in the cyclophosphamide group (0.21 vs. 0.13,
P = 0.09) (Table S6 in the Supplementary Appendix), with 92% of the events occurring in the
first 26 months (Table S7 in the Supplementary
Appendix). Varicella zoster infection occurred in
13 participants (12 in the transplantation group
and 1 in the cyclophosphamide group, P<0.001).
All but two zoster infections occurring in transplant recipients developed 1 to 4 years after transplantation; one episode was disseminated and
none were life-threatening. Five cases of cytomegalovirus reactivation occurred, all more than
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2.5 months after transplantation, with no herpes
simplex or Epstein–Barr virus infections noted.
One transplant recipient had inadequate stemcell mobilization with G-CSF and required cyclophosphamide. All transplant recipients had had
sustained engraftment with neutrophil recovery
by days 8 to 12 and final platelet transfusion by
days 6 to 23.

Discussion
In the SCOT trial, treatment of severe scleroderma with myeloablative therapy and CD34+
selected autologous hematopoietic stem-cell transplantation led to superior long-term outcomes as
compared with cyclophosphamide. The result of
the intention-to-treat analysis of the global rank
composite score at 54 months (the primary end
point) was conclusive even after accounting for
between-group imbalances at baseline. Secondary
per-protocol analyses of global rank composite
scores and traditional end points (overall survival, event-free survival, modified Rodnan skin
score, and DMARD use) further corroborated
this result.
Our results confirm the findings of the Autologous Stem Cell Transplantation International
Scleroderma (ASTIS) trial, including the advantage for patients who had never smoked.12 In the
ASTIS trial, scleroderma relapse (defined as the
need for DMARD therapy) was observed in 22%
of the participants at 12 to 24 months after nonmyeloablative transplantation. In the SCOT trial,
only 9% of transplant recipients had initiated
DMARDs by 24 months (the rate was also 9% at
54 months). Evidence that patients with scleroderma could have significant improvement and
remain free of DMARDs supports transplantation as a treatment for this serious disease. After
transplantation, the burden of severe adverse
events was considerable but limited in onset,
with 96% of serious adverse events occurring in
the first 26 months after transplantation. Overall infection rates were similar in the two groups
with one exception: varicella zoster infection developed in 12 of 33 transplant recipients (36%).
Other toxic effects were consistent with those in
studies of transplantation in other diseases.
Although the global rank composite score has
not been used in studies of scleroderma, similar
approaches have gained acceptance in trials of
other diseases.25-29 The global rank composite
score is not a clinical measure but rather an
n engl j med 378;1

analytic approach that compares every participant
in a study with every other participant on the
basis of a predefined hierarchy of outcomes —
in this case, outcomes specific for severe scleroderma.1,4,9,12 Objective components (death, eventfree survival, and FVC) were scored at a higher
priority than more subjective measures (HAQ-DI
score and modified Rodnan skin score). The validity of this approach is supported by the more
traditional secondary analyses. Use of the global
rank composite score permitted the simultaneous
assessment of multiple disease features as part
of an efficient trial design.
Complications of autologous transplantation
for autoimmune disease include treatment-related
deaths, cancers, and infections.30 Historically, infections are the most common causes of death;
infections tend to cluster in the first month after
transplantation and decrease thereafter.31,32 Although scleroderma is associated with an increased risk of cancer, chemotherapy and irradiation are also associated with increased cancer
risk.33,34 Patients who are exposed to total-body
irradiation are at increased risk for secondary
cancers over a lifetime. Additional follow-up will
be needed to quantify the risk of late cancer in
patients with scleroderma who are treated with
total-body irradiation as well as long-term outcomes of the trial.
Transplant-related mortality of 3% at 54 months
and 6% at 72 months in the SCOT trial was
lower than that previously reported.12,35 No deaths
were observed during the first year (95% confidence interval [CI], 0% to 9.7%). In the ASTIS
trial, treatment-related mortality among 75 nonmyeloablative transplant recipients was 10.7%
(95% CI, 4.5 to 19.0) during the first year.12 Differences in treatment-related mortality could be
due to differences in disease characteristics at
trial entry: none of the SCOT participants had
cardiac involvement or pulmonary arterial hypertension, and fewer had ever smoked. The nonmyeloablative ASTIS trial used high doses of cyclophosphamide for both mobilization (4 g per
square meter, or approximately 100 mg per kilogram) and transplantation (200 mg per kilogram).
A similar high-dose regimen of cyclophosphamide
in conjunction with transplantation was given
to 90 patients with scleroderma and resulted in a
6% treatment-related mortality, with four of the
five deaths during the peritransplantation period
attributable to cardiac complications.35 These data
suggest that high-dose cyclophosphamide may be
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too toxic for some patients with severe scleroderma, particularly in the presence of heart disease.
In contrast to nonmyeloablative regimens, the
conditioning regimen in the SCOT trial was designed to maximally deplete T cells in both the
graft and the host before progenitor-cell immune
reconstitution. The unique property of totalbody irradiation to ablate dividing and resting
autoreactive clones probably contributed to the
durable remissions that we observed, findings
that mirror those of preclinical transplantation
studies in autoimmune disease.36 However, the
mechanisms whereby immune homeostasis leads
to control of autoimmune disease after autologous
transplantation are yet to be fully elucidated.37-40
Our trial has limitations. We enrolled patients with severe internal organ disease and not
solely skin disease, so results may not be generalizable to all patients with scleroderma. The
components of the global rank composite score
and the hierarchy were chosen for this severely
affected cohort and may not be generalizable to
other populations. Although blinding is not possible in a transplantation trial, objective outcomes

of

m e dic i n e

were placed higher in the global rank composite
score hierarchy to mitigate this limitation.
In conclusion, at 54 months after randomization, myeloablative CD34+ selected autologous
hematopoietic stem-cell transplantation resulted
in significantly better clinical outcomes than 12
months of cyclophosphamide. Although there was
greater hematopoietic toxicity and an unquantified
risk of second cancers from exposure to totalbody irradiation, toxic effects should be weighed
against the beneficial results of treatment and
the seriousness of the underlying disease.
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